European Union blocks merger of US firms in cancer screening sector

Illumina said it intends to appeal the decision, which comes just days after a U.S. Federal Trade Commission judge ruled in favor of its acquisition of GRAIL

european union
European Union blocks merger of US firms in cancer screening sector.
AP Brussels
2 min read Last Updated : Sep 06 2022 | 7:22 PM IST

The European Union's anti-trust watchdog announced on Tuesday that it is blocking the buyout of cancer-screening company GRAIL by biotech giant Illumina in a rare move by European regulators against two US companies.

Illumina is a major supplier of next-generation sequencing (NGS) systems for genetic and genomic analysis, while GRAIL is a health company developing blood tests to try to catch cancer early. Illumina announced an $8 billion acquisition of GRAIL in 2020.

But the European Commission, which polices competition issues, said the buyout would have enabled and incentivised Illumina to foreclose GRAIL's rivals, who are dependent on Illumina's technology, from access to an essential input they need to develop and market their own tests.

Commission Executive Vice-President Margrethe Vestager said that it is vital to preserve competition between early cancer detection test developers at this critical stage of development. As Illumina did not put forward remedies that would have solved our concerns, we prohibited the merger.

The commission said it received feedback from several customers and competitors during its probe of the buyout, but Vestager declined to name any of GRAIL's competitors whose interests might have been hurt.

The commission said market players were concerned that Illumina would cut access to its NGS technology to GRAIL's rivals, or otherwise disadvantage them, to gain control over the promising early cancer-detection testing market.

Illumina said it intends to appeal the decision, which comes just days after a U.S. Federal Trade Commission judge ruled in favor of its acquisition of GRAIL.

Illumina can make GRAIL's life-saving multi-cancer early detection test more available, more affordable, and more accessible saving lives and lowering healthcare costs, said Charles Dadswell, General Counsel of Illumina.

We continue to believe, this merger is pro-competitive and will accelerate innovation, he said.

Vestager also said that Illumina appears to have broken EU merger rules by completing the buyout before the commission cleared the move.

This is unheard of. Companies abide by our rules. They require them to not implement a merger before they have been notified and cleared by the commission, she told reporters in Brussels.

Illumina's actions, Vestager said, have created a troublesome situation. Illumina now needs to undo the effects of its actions and unwind the acquisition.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :European UnionUS firmscancer

First Published: Sep 06 2022 | 7:22 PM IST

Next Story